25-Hydroxyvitamin D in Canadian Adults: Biological, Environmental, and Behavioral Correlates
Overview
Orthopedics
Authors
Affiliations
Summary: We assessed vitamin D status and its correlates in the population-based Canadian Multicentre Osteoporosis Study (CaMos). Results showed that serum 25-hydroxyvitamin D levels <75 nmol/L were common. Given Canada's high latitude, attention should be given to strategies for enhancing vitamin D status in the population.
Introduction: Inadequate vitamin D has been implicated as a risk factor for several clinical disorders. We assessed, in a Canadian cohort, vitamin D status and its correlates, based on serum 25-hydroxyvitamin D [25(OH)D], the best functional indicator of vitamin D status.
Methods: We studied 577 men and 1,335 women 35+ years from seven cities across Canada in the randomly selected, population-based Canadian Multicentre Osteoporosis Study (CaMos). Participants completed a comprehensive questionnaire. Serum 25(OH)D was measured by immunoassay. Multivariate linear regression modeling assessed the association between 25(OH)D and determinants of vitamin D status.
Results: Participants (2.3%) were deficient in 25(OH)D (<27.5 nmol/L); a further 18.1% exhibited 25(OH)D insufficiency (27.5-50 nmol/L). Levels <75 nmol/L were evident in 57.5% of men and 60.7% of women and rose to 73.5% in spring (men) and 77.5% in winter (women); 25(OH)D <50 nmol/L was ≤10% year round for those supplementing with ≥400 IU vitamin D/day but was 43.9% among those not supplementing in winter and spring. The strongest predictors of reduced 25(OH)D for both men and women were winter and spring season, BMI ≥30, non-white ethnicity, and lower vitamin D supplementation and its modification by fall and winter.
Conclusions: In this national Canadian cohort, vitamin D levels <75 nmol/L were common, particularly among non-white and obese individuals, and in winter and spring. Vitamin D intake through diet and supplementation and maintenance of normal weight are key modifiable factors for enhancing vitamin D status and thus potentially influencing susceptibility to common chronic diseases.
Kralova M, Jirasko M, Dedeckova E, Hatakova H, Broz P, Simanek V In Vivo. 2024; 39(1):452-458.
PMID: 39740917 PMC: 11705152. DOI: 10.21873/invivo.13848.
Al-Quisi A, A Jamil F, M Al-Anee A, Jassim Muhsen S ScientificWorldJournal. 2024; 2024:9933646.
PMID: 39376220 PMC: 11458301. DOI: 10.1155/2024/9933646.
Sreenivasulu K, Banerjee M, Tomo S, Shukla K, Selvi M, Garg M Metabol Open. 2024; 23:100298.
PMID: 39045138 PMC: 11263621. DOI: 10.1016/j.metop.2024.100298.
Androutsakos T, Politou M, Boti S, Pittaras T, Kontos A, Kordossis T Curr HIV Res. 2024; 22(4):240-248.
PMID: 38874038 DOI: 10.2174/011570162X302844240605104855.
Abouzid M, Burchardt P, Kagan L, Glowka F, Karazniewicz-Lada M Future Cardiol. 2024; 20(3):123-135.
PMID: 38597392 PMC: 11216514. DOI: 10.2217/fca-2023-0129.